目的 肿瘤厌食恶液质综合征是恶性肿瘤临床诊疗常见的复杂综合征，在晚期阶段伴有较高的死亡率，近年来， Ghrelin 及类似物治疗肿瘤恶液质研究进展较大，显示良好的疗效及耐受性，本文就 Ghrelin 及其类似物和相关激素在肿瘤 厌食恶液质综合征中的研究现状及进展作一文献综述。 方法 以“肿瘤恶液质、 Ghrelin、 Ghrelin 类似物、生长激素、胰岛素、 胰岛素生长因子 1”作为关键词检索中文及外文数据库，如 CNKI， Pubmed 等。 结果 阿拉莫林等 Ghrelin 类似物及增敏剂 增加肿瘤恶液质患者瘦体组织，改善症状及生活质量，不促进肿瘤生长。胰岛素、胰岛素生长因子 1、生长激素没有确凿 证据可使肿瘤恶液质治疗获益。 结论 在肿瘤恶液质实验研究中，以阿拉莫林为代表的 Ghrelin 类似物及增敏剂疗效显著， 具备良好的临床应用前景。

Objective Cancer-related anorexia and cachexia syndrome (CACS) is a kind of complex clinical syndrome with a high mortality in advanced stage of cancer. Ghrelin and Ghrelin mimetics have showed excellent effect and tolerance in latest studies. In this paper, we review the present situation and the progress in studies about the effect of Ghrelin, Ghrelin mimetics and related growth factors in CACS. Methods Related articles were obtained through comprehensive search in the database, like CNKI, Pubmed, and so on, with the keywords “cancer, cachexia, Ghrelin, Ghrelin mimetics, growth hormone, insulin, insulin-like growth factor-1”. Results Ghrelin mimetics, like Anamorelin consistently increased lean body mass, improved symptoms and quality of life, and have not shown an increase in tumor proliferation in CACS. There were no substantial evidence to support that growth hormone, insulin and insulin-like growth factor-1 would beneft patients with CACS. Conclusions Ghrelin mimetics and potentiation of ghrelin, represented by Anamorelin have shown positive effects in CACS, and would be applied in clinics in the near future.